Synairgen Share Discussion Threads

[bobaxe1] 28/9/2020 00:06

Interferon decreases with age, hence the need for sng001. https://twitter.com/VirusesImmunity/status/1309872571417079808?s=19Anybody trying to suppress this treatment needs to have a long look in the mirror!!

[andymunchkin] 27/9/2020 23:34

SaidIt b4 RampngCnts rJumingThe sinkingShip lostA pound morePain tomorrow nottingWill stopTheRout.useRfkd loooongNite

[master rsi] 27/9/2020 22:58

Who will win big at this year’s AIM awards?
by Andrew Hore from interactive investor | 25th September 2020

This year’s AIM awards will be announced on 15 October and the shortlists for the individual awards have been revealed. They include many of the old favourites and a few new names – so who is likely to win the 2020 trophies? .........

Best technology
Last year’s winner, medical device developer Creo Medical (LSE:CREO), is back on the shortlist, while cell engineering services provider MaxCyte (LSE:MXCT) won the award in 2016. Both companies have made further progress but the award is likely to be between Renalytix AI (LSE:RENX)and Synairgen (LSE:SNG).

RenalytixAI has developed the KidneyIntelX test that can be used for the early diagnosis and improved management of chronic kidney disease patients. The company has agreed pricing with the US authorities and gained a Nasdaq listing. There is potential for the technology to be used as a companion diagnostic to other treatments.

Respiratory treatments developer Synairgen (LSE:SNG) is one of those AIM drug developers that has been around for years and has made slow, and not always smooth, progress. Inhaled interferon beta treatment SNG001 has been the main focus of the company and it has proved to be a safe and effective treatment for Covid-19 in hospitalised patients. There could be revenues generated from this treatment by the end of this year.

Best guess: Synairgen .......